1L EGFRm+ Lung cancer is rapidly evolving and changing. Tagrisso is leading the pack with ORR of 77% and PFS of 18.9 mos. However, talking about overall survival, Dacomitinib is currently leading with OS of 34.1 mos. As Tagrioss’s final OS data is yet to be declared, the OS in 1L could reach beyond 40 mos. Click here for References Tarceva: EURTAC results; PubMed: lancet oncology; Tarceva Label Iressa: Iressa Label; IPASS data; EPAR_-_Public_assessment_report;
Pembrolizumab demonstrated durable anti-tumor activity in various tumors specially Hodgkin Lymphoma (ORR: 50%, mPFS: 12.2 months, 12 month PFS rate: 59.7%). The results indicate further study of pembrolizumab in pediatric patients with particulate interest in Lymphoma Phase 2 Study results confirms PR rate of 72% with that of phase 1 (71%). Most responses were sustained ≥6 months. Improvements in PN related pain and motor impairment demonstrate that selumetinib can provide clinical benefit Trametinib demonstrated ORR
  Why is it so difficult to develop drugs for children with cancer? What can be done to stimlate investments in the pediatric oncology space?  These questions are central to a new study published by MIT Sloan researchers that explores new business models for funding drug development to treat pediatric cancers.  The presentation sumamrizes the key findings of the study & talks about the challenges  of developing drugs for pediatric cancer–and offers a potential solution. The study

Major Milestones In Cancer Research

Posted by Preeti Parikh on  June 2, 2018
Category: ASCO18, Oncology
Research and development within the cancer field is continuously evolving and progressing. This video highlights the biggest milestones within the field of cancer research spanning 170 years —from the advent of general anesthesia opening the door for cancer surgery in the mid-1800s to the first gene therapy for cancer approved by the Food and Drug Administration in 2017.      
Lymphoma - ASCO18
Abstract 7504: Activity and tolerabilty of the first-in-class anti-CD47 antibody Hu5F9-G4 (5F9) with rituximab tolerated in relapsed/refractory non-Hodgkin lymphoma: Initial phase 1b/2 results. Conclusion: 5F9 + rituximab is a novel immunotherapy that inhibits a key macrophage/cancer checkpoint. It is well tolerated with no MTD reached and has promising clinical activity in rituximab-refractory DLBCL and FL patients including multiple CRs. Phase 2 cohorts are ongoing in indolent lymphoma and DLBCL The U.S. FDA has granted fast